We are an international team of world-leading scientists and clinicians, from the UK and the US, as well as patient advocacy partners, who are working together to deliver CureHeart’s vision. CureHeart is led by Prof Hugh Watkins and Prof Christine Seidman is co-lead. Our team includes Prof David Liu, Prof Eric Olson, Prof Jon Seidman and Prof Matthew Wood.  We work in collaboration with a global partnership of cardiomyopathy charities to ensure the patient’s voice is embedded in, and guides, our research.

Cardiomyopathies are heart muscle diseases that affect 1 person in every 250.  Approximately 260,000 people in the UK, and 1.5 million in the US, are affected; many are unaware that they may be at risk. People with cardiomyopathy often live shorter, impaired lives, and develop symptoms that interfere with daily living. Patients can develop heart failure, and sudden cardiac death can occur.

Current treatments are life-long and expensive, and can cause serious side effects, as well as often not working very well as they cannot stop progression of the disease. Implantable defibrillators can prevent sudden cardiac death, but they do not improve symptoms or protect from heart failure, the major cause of death in patients.  CureHeart want to change this by developing novel therapies and cures for inherited cardiomyopathies.

We are funded by a £30 million research award from the British Heart Foundation.